ENTITY
Celltrion Inc

Celltrion Inc (068270 KS)

644
Analysis
Health Care • South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
bullish•Eubiologics
•13 Jan 2017 00:29

Eubiologics IPO Part 3 - IPO Bookbuilding Results & Personal View

Eubiologics IPO price was set at ₩6,000, the lowest end of the indicative price band, after conducting the demand survey (bookbuilding) (Jan 9-10)...

Logo
585 Views
Share
bullish•Eubiologics
•10 Jan 2017 16:02

Eubiologics IPO Part 2 - Growth Potential & Appropriate Valuation Level

* In Part 2 (as below), I examined the company's business fundamentals in more detail along with its growth potential and appropriate valuation...

Logo
326 Views
Share
bullish•Eubiologics
•08 Jan 2017 02:20

Eubiologics IPO Part 1 - Schedule, Financials & Valuation

Eubiologics is a very "young" vaccine company that develops an oral cholera vaccine product called "Euvichol". This company will be Korea's first...

Logo
487 Views
Share
•31 Dec 2016 06:11

Korea Stock Market Monthly Recap #9 - (December 2016)

The economic hope post Trump win continued to play out in the global equity markets in December. Dow Jones Industrial Average was up 3.3% and...

Logo
558 Views
Share
bearish•Celltrion Healthcare
•27 Dec 2016 13:07

Celltrion Healthcare IPO - Early Review on Key Issues

Celltrion Healthcare, which is Celltrion (068270)’s overseas sales and marketing unit, submitted the application for preliminary screening for...

Logo
363 Views
Share
x